Table 1.

Demographics and clinical information of the preterm infants imaged at bedside with handheld, portable spectral-domain optical coherence tomography (SDOCT), including stage and zone of retinopathy of prematurity (ROP) and any ROP treatment

Eye#	Baby#	Eye	Gestational age (weeks)	Birth weight (g)	Race	Sex	Agea at examination and imaging (weeks)	ROP Stage	Prior treatment
1	1	R	25	640	L	M	32	Z1S0	None
2	1	L	25	640	L	M	32	Z1S0	None
							34	Z1S2	None
							35	Z1S2	None
							36	Z1S3Rb	IVBd
3	2	R	26	790	A	F	32	Z2S1	None
4	3	R	24	624	AA	M	32	Z1S3	None
							39	Z2S3R	IVB
5	4	L	23	475	M	F	34	Z1S3	None
							38	Z1S3R	IVB
6	4	R	23	475	M	F	41	Z2S3R	IVB
7	5	R	25.4	NAc	AA	M	35	Z2S3	None
8	5	L	25.4	NA	AA	M	35	Z2S3	None
							40	Z2S3R	Laser
9	6	L	23.8	650	C/L	F	33	Z1S3R	IVB
10	7	R	22	590	C	M	40	Z1S3R	IVB
							42	Z1S3R	IVB
							44	Z1S3R	IVB
11	7	L	22	590	C	M	40	Z1S3R	IVB
							42	Z1S3R	IVB
12	8	R	23	420	AA	F	41	Z1S4A	Laser/IVB
13	8	L	23	420	AA	F	42	Z1R	Laser/IVB
14	9	R	24.6	644	AA	F	33	Z1S3	IVB
15	9	L	24.6	644	AA	F	33	Z1S3	IVB
16	10	R	24	640	AA	F	39	Z2S4A	Laser/IVB
17	10	L	24	640	AA	F	39	Z2S3R	Laser/IVB
							40	Z2S3R	Laser/IVB
							44	Z2S3R	Laser/IVB
							48	Z2S3R	Laser/IVB
18	11	R	25	NA	AA	M	39	Z2S4B	Laser

^aPostmenstrual age = gestational age + postnasal age

^bR: regressed

^cNA: not available/unknown

^dIVB: intravitreal bevacizumab injection